Logo image of DRMA

DERMATA THERAPEUTICS INC (DRMA) Stock Fundamental Analysis

USA - NASDAQ:DRMA - US2498455045 - Common Stock

3.42 USD
-0.01 (-0.29%)
Last: 10/31/2025, 8:00:01 PM
3.4 USD
-0.02 (-0.58%)
After Hours: 10/31/2025, 8:00:01 PM
Fundamental Rating

2

DRMA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. While DRMA seems to be doing ok healthwise, there are quite some concerns on its profitability. DRMA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year DRMA has reported negative net income.
DRMA had a negative operating cash flow in the past year.
In the past 5 years DRMA always reported negative net income.
DRMA had a negative operating cash flow in each of the past 5 years.
DRMA Yearly Net Income VS EBIT VS OCF VS FCFDRMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

DRMA's Return On Assets of -155.54% is on the low side compared to the rest of the industry. DRMA is outperformed by 86.33% of its industry peers.
DRMA has a Return On Equity of -183.97%. This is in the lower half of the industry: DRMA underperforms 65.36% of its industry peers.
Industry RankSector Rank
ROA -155.54%
ROE -183.97%
ROIC N/A
ROA(3y)-194.6%
ROA(5y)-241.76%
ROE(3y)-356.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DRMA Yearly ROA, ROE, ROICDRMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 1K -1K 2K

1.3 Margins

DRMA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DRMA Yearly Profit, Operating, Gross MarginsDRMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for DRMA has been increased compared to 1 year ago.
Compared to 5 years ago, DRMA has more shares outstanding
DRMA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
DRMA Yearly Shares OutstandingDRMA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50K 100K 150K 200K 250K
DRMA Yearly Total Debt VS Total AssetsDRMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

DRMA has an Altman-Z score of -17.55. This is a bad value and indicates that DRMA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -17.55, DRMA is not doing good in the industry: 82.77% of the companies in the same industry are doing better.
DRMA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -17.55
ROIC/WACCN/A
WACCN/A
DRMA Yearly LT Debt VS Equity VS FCFDRMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

A Current Ratio of 6.47 indicates that DRMA has no problem at all paying its short term obligations.
The Current ratio of DRMA (6.47) is better than 66.85% of its industry peers.
DRMA has a Quick Ratio of 6.47. This indicates that DRMA is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 6.47, DRMA is doing good in the industry, outperforming 67.23% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.47
Quick Ratio 6.47
DRMA Yearly Current Assets VS Current LiabilitesDRMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 21.53% over the past year.
EPS 1Y (TTM)21.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, DRMA will show a very strong growth in Earnings Per Share. The EPS will grow by 38.90% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y91.19%
EPS Next 2Y38.9%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DRMA Yearly EPS VS EstimatesDRMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -2K -4K -6K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DRMA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DRMA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DRMA Price Earnings VS Forward Price EarningsDRMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DRMA Per share dataDRMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30 -40

4.3 Compensation for Growth

DRMA's earnings are expected to grow with 38.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.9%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

DRMA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DERMATA THERAPEUTICS INC

NASDAQ:DRMA (10/31/2025, 8:00:01 PM)

After market: 3.4 -0.02 (-0.58%)

3.42

-0.01 (-0.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/amc
Earnings (Next)N/A N/A
Inst Owners7.46%
Inst Owner ChangeN/A
Ins Owners5.27%
Ins Owner Change0%
Market Cap2.33M
Revenue(TTM)N/A
Net Income(TTM)-10328800
Analysts82.86
Price Target10.2 (198.25%)
Short Float %10.87%
Short Ratio0.38
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.92%
Min EPS beat(2)1.96%
Max EPS beat(2)43.88%
EPS beat(4)3
Avg EPS beat(4)8.86%
Min EPS beat(4)-34.64%
Max EPS beat(4)43.88%
EPS beat(8)5
Avg EPS beat(8)11.11%
EPS beat(12)9
Avg EPS beat(12)14.59%
EPS beat(16)12
Avg EPS beat(16)10.35%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)233.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-562.5%
EPS NY rev (1m)0%
EPS NY rev (3m)-466.42%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.41
P/tB 0.41
EV/EBITDA N/A
EPS(TTM)-47.16
EYN/A
EPS(NY)-6.35
Fwd EYN/A
FCF(TTM)-16.11
FCFYN/A
OCF(TTM)-16.11
OCFYN/A
SpS0
BVpS8.26
TBVpS8.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -155.54%
ROE -183.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-194.6%
ROA(5y)-241.76%
ROE(3y)-356.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.47
Quick Ratio 6.47
Altman-Z -17.55
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.03%
EPS Next Y91.19%
EPS Next 2Y38.9%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-39.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-39.11%
OCF growth 3YN/A
OCF growth 5YN/A

DERMATA THERAPEUTICS INC / DRMA FAQ

What is the ChartMill fundamental rating of DERMATA THERAPEUTICS INC (DRMA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to DRMA.


What is the valuation status of DERMATA THERAPEUTICS INC (DRMA) stock?

ChartMill assigns a valuation rating of 1 / 10 to DERMATA THERAPEUTICS INC (DRMA). This can be considered as Overvalued.


Can you provide the profitability details for DERMATA THERAPEUTICS INC?

DERMATA THERAPEUTICS INC (DRMA) has a profitability rating of 0 / 10.